CongeNIRS: Cardiac Rehabilitation in Congenital Heart Disease: Effects on Brain and Cognitive Functions

Sponsor
Montreal Heart Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT05195788
Collaborator
(none)
100
1
2
13.7
7.3

Study Details

Study Description

Brief Summary

The proposed trial is designed to evaluate the effect of an individualised cardiac rehabilitation program, consisting of aerobic and muscle strengthening exercises, on brain activity and cognitive functions in adults with congenital heart disease

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cardiac rehabilitation
N/A

Detailed Description

Thanks to advances in medical research, individuals born with heart defects (Congenital Heart Disease: CHD), are now 95% more likely to reach adulthood, with around 250,000 adults with CHD currently living in Canada. CHD-related diseases and conditions are extremely common in the adult CHD population, and undermine the successes achieved by medical research. For example, compared to healthy peers, adults with CHD are between 3 to 6 times more likely to experience heart accidents or develop other heart conditions during lifetime. Adults with CHD also have more health problems, and have between 1.5 and 2 increased risk of precocious cognitive decline and dementia. Better lifestyle choices and management of medical risk factors play a crucial role in preventing such problems and in increasing the quality of life of those living with CHD. In this regard, physical activity has been suggested as one of the most cost-effective methods for decreasing mortality and incidence of cardiovascular diseases related to CHD. An increasing body of studies have shown that both physical activity and exercise training improve physical and mental health in adults with CHD, who typically tend to be less active than healthy adults. Although physical activity and exercise training have been shown to enhance cognition and brain activity in individuals with other cardiovascular diseases, such effects in CHD are yet to be investigated.

In the present project, the impact of a cardiac rehabilitation program on brain activity and on cognitive functions will be explored in adults with moderate and severe forms of CHD. The 3-month intervention will include an individualised program consisting of combined aerobic and muscle strengthening exercises provided by certified kinesiologists, to be completed at the research center and at home (hybrid program). Brain imaging technology (fNIRS) will be used to measure changes in brain activity related to the intervention. The benefits on cognitive functions, such as attention, executive functions and memory, will be measured with standardized neuropsychological tests before and after the intervention. The results of this project will contribute to a better understanding of the many benefits of exercise training in individuals with CHD, and will lay the foundations for optimal interventions, targeted to prevent CHD-related conditions and impairments.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The CongeNIRS study uses the prospective, randomised, open-label, blinded end-point (PROBE) design. The participation in this study is expected to be three months and two weeks, comprising three months of physical training and 2 weeks of testing (baseline and three months, one week each).The CongeNIRS study uses the prospective, randomised, open-label, blinded end-point (PROBE) design. The participation in this study is expected to be three months and two weeks, comprising three months of physical training and 2 weeks of testing (baseline and three months, one week each).
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Investigating the Impact of Cardiac Rehabilitation on Brain Activity and Cognition in Adults With Congenital Heart Disease
Actual Study Start Date :
Feb 7, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Participants assigned to the Intervention group will undergo a cardiac rehabilitation program. The program will combine individualized aerobic and muscle strengthening exercises, comprising three sessions per week to be conducted in person at the EPIC center and at home, for a duration of three months. All sessions will be prepared by a certified kinesiologist.

Behavioral: Cardiac rehabilitation
The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.

No Intervention: Control

Participants assigned to the control group will be encouraged to remain at the usual level of physical activity for the duration of the study. At the end of the study, they will gain free access to the same cardiac rehabilitation program provided to the intervention group.

Outcome Measures

Primary Outcome Measures

  1. Change in brain hemodynamics [Baseline, post-intervention at 3 months]

    Neurovascular coupling (Stroop task). This component will be investigated at the cortical level using functional near infrared spectroscopy (fNIRS), and measured in changes in hemodynamics (oxygenated hemoglobin concentration).

Secondary Outcome Measures

  1. Changes in general cognitive functioning [Baseline, post-intervention at 3 months]

    Cognitive performance. This component will be investigated using the Montreal Cognitive Assessment test.

  2. Changes in episodic memory [Baseline, post-intervention at 3 months]

    Memory performance. This component will be investigated using the Rey Auditory Verbal Learning test.

  3. Changes in executive functions [Baseline, post-intervention at 3 months]

    Cognitive performance. This component will be investigated using tests of executive functions (n-back, Trail Making Test, dual task, Stroop), measured in accuracy (composite Z-score).

  4. Changes in processing speed [Baseline, post-intervention at 3 months]

    Cognitive performance. This component will be investigated using tests of executive functions (Trail Making Test, dual task, Stroop), measured in reaction time (composite Z-score).

Other Outcome Measures

  1. Changes in cardiorespiratory fitness [Baseline, post-intervention at 3 months]

    Maximal incremental cardiopulmonary exercise test (VO2 max).

  2. Changes in cardiac hemodynamic [Baseline, post-intervention at 3 months]

    Cardiac output will be measured continuously at rest and during exercise (L/min).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • being able to read, understand and sign the information and consent form;

  • being aged 18 or more at the time of consent;

  • having a diagnosis of congenital heart disease with moderate or severe risk;

  • being referred to the EPIC center in cardiovascular rehabilitation;

  • being able to perform a maximal cardiopulmonary stress test and an exercise training program in accordance with current recommendations for cardiovascular rehabilitation;

  • having Internet access.

Exclusion Criteria:
  • recent major cardiovascular events or interventions <3 months;

  • uncontrolled mental or psychiatric disorder in the last 6 months;

  • genetic syndromes affecting cognition;

  • excessive alcohol consumption (> 15 drinks / week);

  • current participation in other clinical trials;

  • contraindication to stress testing and / or physical training;

  • severe intolerance to physical exercise.

Contacts and Locations

Locations

Site City State Country Postal Code
1 EPIC Center of the Montreal Heart Institute Montréal Quebec Canada H1T 1N6

Sponsors and Collaborators

  • Montreal Heart Institute

Investigators

  • Principal Investigator: Louis Bherer, PhD, EPIC Center of the Montreal Heart Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Louis Bherer, Associate Scientific Director, Direction of Prevention, Montreal Heart Institute
ClinicalTrials.gov Identifier:
NCT05195788
Other Study ID Numbers:
  • MHI 2022-3019
First Posted:
Jan 19, 2022
Last Update Posted:
May 6, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Louis Bherer, Associate Scientific Director, Direction of Prevention, Montreal Heart Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2022